Each film-coated tablet contains :
Ranitidine HCl equivalent to Ranitidine (150 mg)
Ranitidine is a competitive reversible antagonist of histamine at the histamine H2 receptors on the parietal cells, and therefore
effectively inhibits gastric acid secretion.
Ranitidine is absorbed about 50% after oral administration. The peak plasma concentration is reached 2-3 hours after a single
oral dose of 150 mg.
The absorption is not affected significantly by food and antacids. The elimination half life is 2.5 – 3 hours after oral
administration. Ranitidine is excreted through urine.
For short treatment of active duodenal ulcer and gastric ulcer, and for the relief of reflux esophagitis .
For maintenance in duodenal ulcer and gastric ulcer.
For the treatment of pathological hypersecretory conditions (such as Zollinger – Ellison Syndrome, systemic
Renal & hepatic impairment. Pregnancy & lactation. Exclude malignancy before treatment.
Adult 150 mg twice daily or 300 mg at bedtime.
Maintenance: 150 mg at bedtime.
Duration of treatment:
Benign gastric ulcer & post-op ulcer 4 weeks. NSAID-associated ulcer 8-12 weeks. Duodenal ulcer 300 mg twice daily for
4 weeks. Zollinger-Ellison syndrome 150 mg 3 times daily & increased up to a max of 6 g daily. Prophylactic treatment
of stress ulcer & severe cases 150 mg twice daily.
Reduces clearance of warfarin, procainamide, N-acethyl procainamide, increase midazolam absorption but decrease
Film-coated Tablet 150 mg x 50’s Reg.No. DKL0721015217A1
Storage : Store in a cool (15 – 25C) and dry place.
On medical prescription only.